CliffBio
biologic

Rylaze

asparaginase erwinia chrysanthemi (recombinant)-rywn

Loss of exclusivityJune 2033projected — 12-year biologic exclusivity estimate
CompanyJazz Pharmaceuticals Ireland Limited

Drug detail

Brand nameRylaze
Active ingredientasparaginase erwinia chrysanthemi (recombinant)-rywn
Strength10MG/0.5ML
Dosage formInjection
RouteIntramuscular
ModalityBiologic
FDA approvalJune 2021
Marketing statusRx

More from Jazz Pharmaceuticals Ireland Limited

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Rylaze patent cliff — loss of exclusivity June 2033 | CliffBio